Target-First vs. Modality-First: Identifying Disease-Driven Targets to Maximize Proximity-Based Therapeutic Impact
Time: 9:30 am
day: Day One
Details:
- Why should drug developers take a ‘target-first’ approach rather than retrofitting induced proximity strategies to unsuitable targets to improve translational success and avoid costly late-stage failures?
- How can chemical biology strategies be leveraged to fine-tune target-ligand interactions, ensuring induced proximity drugs achieve optimal selectivity, potency, and drug-like properties?
- Which disease areas offer the highest potential for induced proximity applications, and how to determine the best induced proximity strategy for a given target to maximize therapeutic impact and patient benefit?